Clinical trials
Phase 1/2 Breast Neoplasms trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
66 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 3 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 4 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 6 |
| 2023 | 6 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 25 |
| Recruiting | 17 |
| Active, not recruiting | 13 |
| Terminated | 9 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 8 |
| AstraZeneca | 6 |
| Pfizer | 6 |
| Hoffmann-La Roche | 5 |
| Eli Lilly and Company | 3 |
| Puma Biotechnology, Inc. | 3 |
| Sanofi | 3 |
| Genentech, Inc. | 2 |
| Spanish Breast Cancer Research Group | 2 |
| Stemline Therapeutics, Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 66 |
| Ovarian Neoplasms | 12 |
| Endometrial Neoplasms | 9 |
| Carcinoma, Non-Small-Cell Lung | 8 |
| Neoplasm Metastasis | 7 |
| Neoplasms | 7 |
| Head and Neck Neoplasms | 6 |
| Triple Negative Breast Neoplasms | 6 |
| Colorectal Neoplasms | 5 |
| Lung Neoplasms | 4 |
Trials
Showing 1 to 25 of 66. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.